Yuri Nikiforov

Interpace Biosciences Announces Contract for Thyroid Testing with Blue Cross Blue Shield of Illinois

Retrieved on: 
Thursday, February 25, 2021
Anatomy, Thyroid disease, Organ systems, Glands, Thyroid cancer, Follicular thyroid cancer, Thyroid, Medullary thyroid cancer, Yuri Nikiforov

Tom Burnell, President and CEO of Interpace Biosciences, stated, We are pleased that Blue Cross Blue Shield of Illinois, a division of one of the largest payers in United States, Health Care Services Corporation, has agreed to contract with us for our molecular tests, making them available to their members on an in-network basis.

Key Points: 
  • Tom Burnell, President and CEO of Interpace Biosciences, stated, We are pleased that Blue Cross Blue Shield of Illinois, a division of one of the largest payers in United States, Health Care Services Corporation, has agreed to contract with us for our molecular tests, making them available to their members on an in-network basis.
  • ThyGeNEXT utilizes state-of-the-art next-generation sequencing (NGS) to identify more than 100 genetic alterations associated with papillary and follicular thyroid carcinomas, the two most common forms of thyroid cancer, as well as Medullary Thyroid Carcinoma.
  • ThyGeNEXT and ThyraMIR reflex testing yields high predictive value in determining the presence and absence of cancer in thyroid nodules.
  • Pharma services, through Interpace Pharma Solutions, provides pharmacogenomics testing, genotyping, biorepository, and other customized services to the pharmaceutical and biotech industries.

Global Thyroid Cancer Industry (2020 to 2024) - Evaluate Commercial Market Opportunities - ResearchAndMarkets.com

Retrieved on: 
Thursday, September 10, 2020
Health, Pharmaceutical, Anatomy, RTT, Endocrine diseases, Endocrine system, Glands, Thyroid, Cancer, Thyroid disease, Yuri Nikiforov

The "Global Thyroid Cancer Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Thyroid Cancer Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.
  • The research report provides comprehensive insights into the Thyroid Cancer pipeline, epidemiology, market valuations, drug sales, market forecast, drug forecasts, and market shares.
  • This research covers the following: Thyroid Cancer treatment options, Thyroid Cancer late stage clinical trials pipeline, Thyroid Cancer prevalence by countries, Thyroid Cancer market size and forecast by countries, key market events and trends, drug sales and forecast by countries, and market shares by countries.
  • Thyroid Cancer pipeline: Find out drugs in clinical trials for the treatment of Thyroid Cancer by development phase 3, phase 2, and phase 1, by pharmacological class and company
    Thyroid Cancer drugs: Identify key drugs marketed and prescribed for Thyroid Cancer in the US, including trade name, molecule name, and company
    Thyroid Cancer market valuations: Find out the market size for Thyroid Cancer drugs in 2019 by countries.

Interpace Announces Acceptance of Seminal Clinical Validation Study for Thyroid Assays

Retrieved on: 
Tuesday, July 21, 2020
Thyroid disease, Glands, Organ systems, Endocrine system, Thyroid cancer, Thyroid, Follicular thyroid cancer, Medullary thyroid cancer, Papillary thyroid cancer, Yuri Nikiforov

Sites participating in this multicentered study included Cedars-Sinai Medical Center, Jackson Thyroid & Endocrine Clinic, University of Michigan, Massachusetts General Hospital/Harvard Medical School, and the University of Arkansas for Medical Sciences.

Key Points: 
  • Sites participating in this multicentered study included Cedars-Sinai Medical Center, Jackson Thyroid & Endocrine Clinic, University of Michigan, Massachusetts General Hospital/Harvard Medical School, and the University of Arkansas for Medical Sciences.
  • ThyGeNEXT utilizes state-of-the-art next-generation sequencing (NGS) to identify more than 100 genetic alterations associated with papillary and follicular thyroid carcinomas, the two most common forms of thyroid cancer, as well as Medullary Thyroid Carcinoma.
  • MicroRNAs are small, non-coding RNAs that bind to messenger RNA and regulate expression of genes involved in human cancers, including every subtype of thyroid cancer.
  • ThyGeNEXT and ThyraMIR reflex testing yields high predictive value in determining the presence and absence of cancer in thyroid nodules.